<DOC>
	<DOCNO>NCT00359086</DOCNO>
	<brief_summary>In study , MGCD0103 , new anticancer drug investigation , give three time weekly patient relapse refractory lymphoma .</brief_summary>
	<brief_title>Study MGCD0103 Given Three Times Weekly Patients With Relapsed Refractory Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Pathologic confirmation relapse refractory lymphoma . 1 . DLBCL stage IIIV 2 . Follicular lymphoma At least one site measurable disease ( â‰¥ 2.0 cm conventional technique ; physical exam [ PE ] , CT , Xray , MRI ) . Prior treatment : 1 . DLBCL cohort : Disease progression follow initial therapy transplant ( unless patient ineligible refuse transplant ) . There limit number prior therapy . 2 . Follicular lymphoma cohort : Follicular lymphoma relapse follow refractory standard therapy and/or exist therapy eligible unlikely achieve clinical benefit therapy . Patients must fail 3 prior therapy . Must least one follow consider related disease : 1 . Local symptom due progressive bulky nodal disease . 2 . Compromise normal organ function due progressive bulky disease . 3 . Presence systemic B symptom . 4 . Presence symptomatic extranodal disease . 5 . Cytopenias due extensive bone marrow infiltration , autoimmune hemolytic anemia thrombocytopenia , hypersplenism . ECOG performance status 0 1 . Aged 18 year old . Laboratory requirement . Patients another active cancer ( exclude basal cell carcinoma cervical intraepithelial neoplasia [ CIN/cervical situ ] melanoma situ ) . Prior history cancer allow , long active disease . Pregnant lactating woman . Patients uncontrolled intercurrent illness , active uncontrolled infection , fever &gt; 38.5 Celsius ( due tumor fever ) day schedule dosing . Patients history pericardial disease . Patients small , moderate large pericardial effusion patient diagnosis pericarditis . Patients significant cardiac abnormality . Patients serious illness , medical condition , medical history would likely interfere patient 's participation study interpretation result . Patients treat investigational drug within 28 day prior study initiation . Known hypersensitivity HDAC inhibitor component MGCD0103 . Known human immunodeficiency virus ( HIV ) active Hepatitis B C. Central nervous system lymphoma lymphoma involve leptomeningeal area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Relapsed Refractory Lymphoma</keyword>
	<keyword>Phase II</keyword>
</DOC>